Assessment of novel biomarkers: sTREM-1, pentraxin-3 and pro-adrenomedullin in the early diagnosis of neonatal early onset sepsis.

BACKGROUND Early onset bacterial sepsis in neonates (EOS) is recognized as an important health condition. Early diagnosis is crucial. However, blood culture results are released in 48-72 hours. Many biomarkers have been investigated but none have been accepted as the gold standard. This study aimed to investigate the diagnostic value of the molecules: soluble form of triggering receptor expressed on myeloid cells-1 (sTREM-1), pentraxin-3 (PTX-3) and pro adrenomedullin (pro-ADM) in EOS and compare with currently used biomarkers. METHODS In this multicenter prospective study, patients were enrolled from different NICUs around the Turkey. Patient data were collected via web-based registry system from attending centers. Neonates, hospitalized with a suspicion of EOS were enrolled. Blood culture and routine blood tests were collected and a serum sample was obtained and kept in - 80°C for studying the molecules. According to laboratory results, patients were divided into three groups as; proven sepsis, clinical sepsis and control group. Groups were compared in terms of demographic, clinical and laboratory findings. The primary outcome of the study was to assess any difference between groups in terms of the diagnostic value of the markers aforementioned. RESULTS A total of 130 patients were enrolled; proven sepsis (n = 38), clinical sepsis (n = 53) and control (n = 41) groups. Groups were similar in terms of demographic findings; mean WBC (P = 0.445), procalcitonin (PCT) (P = 0.083) and IL-6 (P = 0.814) levels. Mean C-reactive protein (CRP) level was significantly higher in clinical sepsis and proven sepsis groups compared to control group (P <  0.001). Mean PTX-3 (P = 0.547), pro-ADM (P = 0.766) and sTREM-1 (P = 0.838) levels were similar between groups. CONCLUSION These promising molecules failed to help in early diagnosis of EOS. Their relation to correlation with disease progression may make more sense as they seem to be expressed in higher amounts with the progression of the disease in previous studies. CRP was the most frequently used biomarker for detecting the sepsis in our study population.

[1]  Germán Fajardo,et al.  Early Onset Neonatal Sepsis; Diagnostic Value of Some Laboratory Tests , 2018, International Journal of Medical and Surgical Sciences.

[2]  Germán Fajardo,et al.  Clinical and Epidemiological Characteristics in Newborns with Early Sepsis , 2018, International Journal of Medical and Surgical Sciences.

[3]  S. Wong,et al.  Pentraxin-3 as a marker of sepsis severity and predictor of mortality outcomes: A systematic review and meta-analysis. , 2018, The Journal of infection.

[4]  R. Milewski,et al.  Soluble TREM-1 Serum Level can Early Predict Mortality of Patients with Sepsis, Severe Sepsis and Septic Shock , 2017, Archivum Immunologiae et Therapiae Experimentalis.

[5]  R. Farhadi,et al.  Pentraxin 3 in neonates with and without diagnosis of pulmonary hypertension. , 2017, Clinical biochemistry.

[6]  Jong-seo Yoon,et al.  Pentraxin 3 as a clinical marker in children with lower respiratory tract infection , 2015, Pediatric pulmonology.

[7]  S. Kurtoğlu,et al.  Pentraxin 3 concentrations of the mothers with preterm premature rupture of membranes and their neonates, and early neonatal outcome , 2015, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[8]  F. Castorena-Torres,et al.  Can sTREM-1 predict septic shock & death in late-onset neonatal sepsis? A pilot study. , 2015, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[9]  N. Andrawes,et al.  Circulating soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) as diagnostic and prognostic marker in neonatal sepsis. , 2014, Cytokine.

[10]  R. Ozdemir,et al.  Proadrenomedullin as a prognostic marker in neonatal sepsis , 2012, Pediatric Research.

[11]  O. Levy,et al.  Development of Newborn and Infant Vaccines , 2011, Science Translational Medicine.

[12]  Fabio Natale,et al.  C reactive protein and procalcitonin: reference intervals for preterm and term newborns during the early neonatal period. , 2011, Clinica chimica acta; international journal of clinical chemistry.

[13]  A. Hagag,et al.  Prognostic value of plasma pro-adrenomedullin and antithrombin levels in neonatal sepsis , 2011, Indian pediatrics.

[14]  B. Stoll,et al.  International perspective on early-onset neonatal sepsis. , 2010, Clinics in perinatology.

[15]  W. Benitz.  Adjunct laboratory tests in the diagnosis of early-onset neonatal sepsis. , 2010, Clinics in perinatology.

[16]  A. Mantovani,et al.  PENTRAXIN 3 AND C-REACTIVE PROTEIN IN SEVERE MENINGOCOCCAL DISEASE , 2009, Shock.

[17]  M. Christ-Crain,et al.  Circulating levels of soluble triggering receptor expressed on myeloid cells (sTREM)-1 in community-acquired pneumonia. , 2007, Critical care medicine.

[18]  Barbara Bottazzi,et al.  Pentraxins in Innate Immunity: From C-Reactive Protein to the Long Pentraxin PTX3 , 2007, Journal of Clinical Immunology.

[19]  P. W. Grosvenor,et al.  Mechanisms of adrenomedullin antimicrobial action , 2006, Peptides.

[20]  J. Andrejaitienė.  [The diagnostic value of procalcitonin in severe sepsis]. , 2006, Medicina.

[21]  J. Struck,et al.  Mid-regional pro-adrenomedullin as a prognostic marker in sepsis: an observational study , 2005, Critical care.

[22]  S. Zakynthinos,et al.  Does soluble triggering receptor expressed on myeloid cells‐1 play any role in the pathogenesis of septic shock? , 2005, Clinical and experimental immunology.

[23]  S. Cousens,et al.  4 million neonatal deaths: When? Where? Why? , 2005, The Lancet.

[24]  J. Struck,et al.  Identification of an Adrenomedullin precursor fragment in plasma of sepsis patients , 2004, Peptides.

[25]  P. Bollaert,et al.  Plasma Level of a Triggering Receptor Expressed on Myeloid Cells-1: Its Diagnostic Accuracy in Patients with Suspected Sepsis , 2004, Annals of Internal Medicine.

[26]  M. Béné,et al.  Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia. , 2004, The New England journal of medicine.

[27]  C. Hart,et al.  Procalcitonin as a diagnostic marker of meningococcal disease in children presenting with fever and a rash , 2002, Archives of disease in childhood.

[28]  S. Cuzzocrea,et al.  Effects of Melatonin Treatment in Septic Newborns , 2001, Pediatric Research.

[29]  M. Colonna,et al.  TREM-1 amplifies inflammation and is a crucial mediator of septic shock , 2001, Nature.

[30]  D. Gendrel,et al.  Procalcitonin as a marker of bacterial infection. , 2000, The Pediatric infectious disease journal.

[31]  M. Colonna,et al.  Cutting Edge: Inflammatory Responses Can Be Triggered by TREM-1, a Novel Receptor Expressed on Neutrophils and Monocytes1 , 2000, The Journal of Immunology.

[32]  P. Preuss,et al.  High levels of circulating adrenomedullin in severe illness: correlation with C-reactive protein and evidence against the adrenal medulla as site of origin. , 2009, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[33]  L. Weisman,et al.  Novel approaches to the prevention and therapy of neonatal bacterial sepsis. , 1997, Clinics in perinatology.

[34]  Y. Hattori,et al.  Up-regulation of rat adrenomedullin gene expression by endotoxin: relation to nitric oxide synthesis. , 1996, Life sciences.

[35]  F. Marumo,et al.  Characterization of immunoreactive adrenomedullin in human plasma and urine. , 1995, Life sciences.

[36]  M. Assicot,et al.  High serum procalcitonin concentrations in patients with sepsis and infection , 1993, The Lancet.